COVID R&D consortium launches I-SPY adaptive trial with Quantum Leap
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
The COVID R&D consortium is making good on its intention to push forward experimental therapies as fast as possible, partnering with Quantum Health to launch an I-SPY adaptive trial to evaluate 10-20 agents within a year to treat ARDS, the late-stage respiratory failure that can lead to death in COVID-19. The trial is the first output